New hope for tough pancreatic cancer: targeted drug trial launches
Disease control
Not yet recruiting
This study tests a drug called lorigerlimab in people with advanced pancreatic cancer that has a specific genetic makeup (BRCA, PALB2, or RAD51C/D mutations). The goal is to see if the drug can shrink tumors. About 40 adults will take part, and the study is not yet recruiting.
Phase: PHASE2 • Sponsor: Peter Hosein, MD • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC